Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Currently known SARS-CoV-2 strains
- Likelihood of mutating into a more lethal form of SARS-CoV-2
- Spike proteins and their role in viral entry into human cells
- SARS-CoV-2 is mutating into a more transmissible or infectious form
- Implications of new SARS-CoV-2 variants on public health and vaccine development
- Importance of continuing genetic surveillance of the virus.
Biography
Dr. Montefiori is Professor and Director of the Laboratory for HIV and COVID-19 Vaccine Research & Development in the Department of Surgery, Division of Surgical Sciences at Duke University Medical Center. His major research interests are viral immunology and HIV and COVID-19 vaccine development, with a special emphasis on neutralizing antibodies. Dr. Montefiori directs a large vaccine immune monitoring program that operates in compliance with Good Clinical Laboratory Practice and has served as a national and international resource for standardized assessments of neutralizing antibody responses in preclinical and clinical trials of candidate HIV vaccines since 1988. More recently he turned his attention to SARS-CoV-2, with a special interest in emerging variants and how they might impact transmission and vaccines. His laboratory also measures neutralizing antibody responses in preclinical and clinical studies of COVID-19 vaccines. He has published over 700 original research papers that have helped shape the scientific rationale for antibody-based vaccines.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Montefiori, D. (2021, January 14). SARS-CoV-2 mutations: phenotypes and implications for vaccine development [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/DWEA6002.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. David Montefiori has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)